LGM Pharma

Gabapentin Enacarbil

CAS No: 478296-72-9

Gabapentin Enacarbil

LGM Pharma is a Gabapentin Enacarbil 478296-72-9 active pharmaceutical ingredient supplier distributor, based in the USA.

Questions? Call our customer API support number 1-(800)-881-8210.

LGM Pharma offers this active ingredient but not the finished dosage forms.

Inquire about Gabapentin Enacarbil

Product Details:

CAS No: 478296-72-9
Molecular Weight: 329.389 g/mol
PubChem: 9883933
Chemical Formula: C16H27N1O6
Assay/Purity: Typically NLT 98%
IUPAC Name: 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid

Gabapentin Enacarbil News:

  • Gabapentin Enacarbil, CAS# 478296-72-9, is also known as Horizant, which is marketed by GlaxoSmithKline.
  • Gabapentin enacarbil is the first medication in its class to be approved for the treatment of moderate-to-severe primary Restless Legs Syndrome.
  • The once daily dose of gabapentin enacarbil is typically taken at 5pm.
  • Symptoms of RLS tend to occur during periods of rest or inactivity, such as nighttime. There is currently no cure for this chronic condition.
  • Restless legs syndrome may also known as Willis-Ekbom disease, or WED.
  • RLS adversely affects 2-3 percent of the U.S. population.
  • One clinical trial of patients who received gabapentin enacarbil indicated that 67.6 percent of these patients reported a 30 percent reduction in pain associated with their RLS symptoms after being dosed with this drug.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization
  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials